Table 4. The relationship between clinic-pathological characteristics of patients with high-grade inflammatory cell infiltrate primary operable invasive ductal breast cancer and cancer-specific survival.

	Univariate survival analysis		Multivariate survival analysis
	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
Age (<50/>50 years)	1.43 (0.82–2.52)	0.211
Size (⩽20/21–50/>50 mm)	2.57 (1.67–3.95)	<0.001		0.064
Grade (I/II/III)	1.84 (1.25–2.68)	0.002		0.299
Involved lymph node (0/1–3/>3)	2.45 (1.80–3.33)	<0.001		0.255
Oestrogen-receptor status status (ER−/ER+)	0.41(0.25–0.66)	<0.001		0.956
Progesterone-receptor status (PR−/PR+)	0.35(0.20–0.61)	<0.001		0.713
HER-2 status (HER-2−/HER-2+)	1.66 (0.93–2.95)	0.086		0.678
Ki-67/ MIB1 proliferation index (Low Ki-67/high Ki-67)	1.76 (1.06–2.91)	0.028		0.371
Lymphovascular invasion (Absent/present)	4.82 (2.48–9.34)	<0.001	5.66 (1.92–16.65)	0.002
Innate immune response
Tumour macrophage infiltrate (tertiles)	0.71 (0.51–0.98)	0.035		0.056
Adaptive immune response
Tumour lymphocyte infiltrate (Low/high)	0.13 (0.07–0.23)	<0.001	0.21 (0.09–0.50)	<0.001
Tumour lymphocyte infiltrate/tumour plasma cell infiltrate ratio (tertiles)	0.33 (0.22–0.48)	<0.001		0.245
Tumour CD8+ T-lymphocytic infiltrate (tertiles)	0.55 (0.40–0.76)	<0.001		0.851
Tumour CD138+ B-lymphocytic infiltrate (tertiles)	1.92 (1.41–2.62)	<0.001		0.194
Tumour CD8+ infiltrate/tumour CD138+ infiltrate ratio (tertiles)	0.40 (0.27–0.59)	<0.001	0.48 (0.31–0.76)	0.002